Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.46 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.35 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.35 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.35 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.32 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.32 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | FAP | Q12884 | 1/20 | 0.31 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.31 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.31 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23586947 | 1.00 | SLC7A5 (0.46) | SLC7A5SLC1A2SLC1A3SLC1A1FOLH1 | |
| SCHEMBL17234150 | 1.00 | SLC7A5 (0.46) | SLC7A5SLC1A2SLC1A3SLC1A1FOLH1 | |
| SCHEMBL17234225 | 1.00 | SLC7A5 (0.46) | SLC7A5SLC1A2SLC1A3SLC1A1FOLH1 | |
| SCHEMBL17234221 | 1.00 | SLC7A5 (0.46) | SLC7A5SLC1A2SLC1A3SLC1A1FOLH1 | |
| SCHEMBL17234149 | 1.00 | SLC7A5 (0.46) | SLC7A5SLC1A2SLC1A3SLC1A1FOLH1 | |
| SCHEMBL10056006 | 0.82 | SLC7A5 (0.50) | SLC7A5SLC1A2SLC1A3SLC1A1DPP4 | |
| SCHEMBL17234433 | 0.80 | FOLH1 (0.33) | SLC7A5FOLH1NAALAD2TP53NOS3 | |
| SCHEMBL17234442 | 0.80 | FOLH1 (0.33) | SLC7A5FOLH1NAALAD2TP53NOS3 | |
| SCHEMBL24241819 | 0.80 | FOLH1 (0.33) | SLC7A5FOLH1NAALAD2TP53NOS3 | |
| SCHEMBL17030071 | 0.80 | FOLH1 (0.33) | SLC7A5FOLH1NAALAD2TP53NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3224359-B1 | ARGININE IMPROVES POLYMERASE STORAGE STABILITY | BIO RAD LABORATORIES INC (US) | 2023-10-25 | — | — | EP | claimed |
| CN-114214061-B | Polyethylene glycol modified zwitterionic fluorescent probe, preparation and application thereof | 北京大学 | 2022-05-17 | — | — | CN | claimed |
| CN-114214061-A | Polyethylene glycol modified zwitterionic fluorescent probe, preparation and application thereof | 北京大学 | 2022-03-22 | — | — | CN | claimed |
| US-5658885-A | OLIGOPEPTIDES; ANTICOAGULANTS; ENZYME INHIBITORS; THROMBIN | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-08-19 | — | — | US | claimed |
| EP-3224359-B1 | ARGININE IMPROVES POLYMERASE STORAGE STABILITY | BIO RAD LABORATORIES INC (US) | 2023-10-25 | — | — | EP | disclosed |
| CN-115379831-A | Nanoparticles encapsulating small molecules | 苏黎世联邦理工学院 | 2022-11-22 | — | — | CN | disclosed |
| CN-114214061-B | Polyethylene glycol modified zwitterionic fluorescent probe, preparation and application thereof | 北京大学 | 2022-05-17 | — | — | CN | disclosed |
| CN-114214061-A | Polyethylene glycol modified zwitterionic fluorescent probe, preparation and application thereof | 北京大学 | 2022-03-22 | — | — | CN | disclosed |
| EP-3950673-A1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | Inspirna, Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| EP-3137447-B1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | RGENIX INC (US) | 2021-06-30 | — | — | EP | disclosed |
| US-10053676-B2 | Arginine improves polymerase storage stability | BIO-RAD LABORATORIES, INC. (US) | 2018-08-21 | — | — | US | disclosed |
| US-20160145587-A1 | ARGININE IMPROVES POLYMERASE STORAGE STABILITY | BIO-RAD LABORATORIES, INC. | 2016-05-26 | — | — | US | disclosed |
| US-20020065248-A1 | Inhibitors of hepatitis C virus NS3 protease | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-05-30 | — | — | US | disclosed |
| EP-1196436-A2 | PEPTIDE BORONIC ACID INHIBITORS OF HEPATITIS C VIRUS PROTEASE | Bristol-Myers Squibb Pharma Company (US) | 2002-04-17 | — | — | EP | disclosed |
| WO-2001064678-A2 | INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-09-07 | — | — | WO | disclosed |
| WO-2001040262-A1 | ALPHA-KETOAMIDE INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-06-07 | — | — | WO | disclosed |
| WO-2001002424-A2 | PEPTIDE BORONIC ACID INHIBITORS OF HEPATITIS C VIRUS PROTEASE | DU PONT PHARMACEUTICALS COMPANY (US) | 2001-01-11 | — | — | WO | disclosed |
| US-5658885-A | OLIGOPEPTIDES; ANTICOAGULANTS; ENZYME INHIBITORS; THROMBIN | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-08-19 | — | — | US | disclosed |
| EP-0787010-A1 | AMIDINO AND GUANIDINO SUBSTITUTED INHIBITORS OF TRYPSIN-LIKE ENZYMES | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-08-06 | — | — | EP | disclosed |
| WO-1996012499-A1 | AMIDINO AND GUANIDINO SUBSTITUTED INHIBITORS OF TRYPSIN-LIKE ENZYMES | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020065248-A1 | Inhibitors of hepatitis C virus NS3 protease | TMPRSS15, CTRC, CPN1 | SLC7A5 860/4885SLC1A2 3427/4885SLC1A3 2604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.